Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aspire Biopharma Holdings, Inc. - Common Stock
(NQ:
ASBP
)
0.6078
-0.5822 (-48.92%)
Streaming Delayed Price
Updated: 2:30 PM EDT, Apr 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aspire Biopharma Holdings, Inc. - Common Stock
< Previous
1
2
Next >
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
Today 8:00 EDT
Via
ACCESS Newswire
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion
March 19, 2026
Via
ACCESS Newswire
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
March 17, 2026
Via
ACCESS Newswire
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
March 12, 2026
Via
ACCESS Newswire
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
March 10, 2026
Via
ACCESS Newswire
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
March 03, 2026
Via
ACCESS Newswire
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
February 25, 2026
Via
ACCESS Newswire
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
February 20, 2026
Via
ACCESS Newswire
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
February 19, 2026
Via
ACCESS Newswire
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
February 17, 2026
Via
ACCESS Newswire
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
February 13, 2026
Via
ACCESS Newswire
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
February 12, 2026
Via
ACCESS Newswire
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
February 11, 2026
Via
ACCESS Newswire
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 10, 2026
Via
ACCESS Newswire
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
February 05, 2026
Via
ACCESS Newswire
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
February 03, 2026
Via
ACCESS Newswire
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
January 22, 2026
Via
ACCESS Newswire
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
January 21, 2026
Via
ACCESS Newswire
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
January 20, 2026
Via
ACCESS Newswire
Aspire Biopharma Announces Reverse Stock Split
January 14, 2026
Via
ACCESS Newswire
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
January 07, 2026
Via
ACCESS Newswire
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
December 18, 2025
Via
ACCESS Newswire
Brookmount Gold (OTC: BMXI) Profitable Q3 2025, Gold Production, Spinoff Dividends Takes Shape – More Stocks Inside
December 15, 2025
Via
AB Newswire
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
December 12, 2025
Via
ACCESS Newswire
Aspire Biopharma Provides Q3 2025 Business Update
December 04, 2025
Via
ACCESS Newswire
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
December 02, 2025
Via
ACCESS Newswire
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
November 26, 2025
Via
ACCESS Newswire
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
November 06, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
October 06, 2025
Via
ACCESS Newswire
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
October 03, 2025
Via
ACCESS Newswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
